NCT07203729 2026-03-16The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting184 enrolled
NCT06875128 2026-03-13Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant DiseaseDelcath Systems Inc.Phase 2 Recruiting90 enrolled
NCT07461454 2026-03-10YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerMediLink Therapeutics (Suzhou) Co., Ltd.Phase 3 Not yet recruiting376 enrolled